# Efficacy Study of IL-21 to Treat Metastatic Melanoma

> **NCT00336986** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 54 (actual)

## Conditions studied

- Cancer
- Malignant Melanoma

## Interventions

- **DRUG:** recombinant interleukin-21

## Key facts

- **NCT ID:** NCT00336986
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336986, "Efficacy Study of IL-21 to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00336986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*